Category Archives: CTXR

Citius Pharmaceuticals 23Q4 Update

Citius Pharmaceuticals (CTXR) posted a 23Q4 loss of $11.1 million or $0.07 per share, $0.01 more than my estimate, mostly because of higher than expected stock-based compensation and $1.15 million for a deemed dividend associated with the one-year extension of … Continue reading

Posted in CTXR, Health Care | Tagged | Comments Off on Citius Pharmaceuticals 23Q4 Update

Citius Pharmaceuticals (CTXR) 23Q3 Update

Citius Pharmaceuticals (CTXR) posted a 23Q3 loss of $8.5 million or $0.06 per share, $0.01 less than my estimate, mostly because of a $1.1 million decrease in R&D spending associated with all of its clinical programs (except for Halo-Lido, a … Continue reading

Posted in CTXR, Health Care | Tagged | Comments Off on Citius Pharmaceuticals (CTXR) 23Q3 Update

Citius Pharmaceuticals (CTXR) 23Q2 Update Report

Citius Pharmaceuticals (CTXR) posted a 23Q2 loss of $0.07 per share, $0.02 more than I had anticipated, mostly because of higher R&D spending associated with the ongoing clinical trials of Mino-Lok and Halo-Lido and also due to pre-launch and market … Continue reading

Posted in CTXR, Health Care | Tagged | Comments Off on Citius Pharmaceuticals (CTXR) 23Q2 Update Report

Citius Pharma (CTXR) Completes $15 Million Direct Registered Offering

Last night, Citius Pharmaceuticals (CTXR) reported that it had completed its 12.5 million share direct offering, issuing 12.5 million shares at $1.20 per share with attached warrants exercisable at $1.50 per share. In total, the offering generated gross proceeds of … Continue reading

Posted in CTXR, Health Care | Tagged | Comments Off on Citius Pharma (CTXR) Completes $15 Million Direct Registered Offering

Citius Pharmaceuticals (CTXR) 23Q1 Update

Citius Pharmaceuticals (CTXR) posted a 23Q1 loss of $0.02 per share, better than I had anticipated, mostly because of a $3.6 gain on the sale of net operating loss carryforwards (equivalent to $0.02 per share) from the State of New … Continue reading

Posted in CTXR, Health Care | Tagged | Comments Off on Citius Pharmaceuticals (CTXR) 23Q1 Update

Citius (CTXR) at Sidoti

I recently had the opportunity to view a presentation and ask questions of Leonard Mazur at the Sidoti MicroCap Conference on January 18.  Mr. Mazur helped fill in some of the gaps in my knowledge about company and its plans … Continue reading

Posted in CTXR, Health Care | Tagged | Comments Off on Citius (CTXR) at Sidoti

Citius Pharmaceuticals (CTXR) 22Q4 Update

In 2022, Citius Pharmaceuticals completed its Phase 3 trial for I/ONTAK, indicated for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL) and submitted its Biologics Licensing Application to the FDA.  It has a PDUFA target date of July … Continue reading

Posted in CTXR, Health Care | Tagged | Comments Off on Citius Pharmaceuticals (CTXR) 22Q4 Update

Citius Pharmaceuticals (CTXR) 22Q3 Update

Citius Pharmaceuticals reported a third quarter loss of $8.9 million or $0.06 per share, compared with last year’s loss of $7.3 million or $0.05 per share.  As an early stage drug development company, Citius currently generates no revenues.  The loss … Continue reading

Posted in CTXR, Health Care | Tagged | Comments Off on Citius Pharmaceuticals (CTXR) 22Q3 Update

Citius Announces Its Intention to Spin-Off I/ONTAK

Earlier today, Citius Pharmaceuticals issued a press release announcing its intention to spin-off its late stage oncology candidate, I/ONTAK, to a new, standalone publicly-traded company. In making the announcement, the company said that it believed that the market has not … Continue reading

Posted in CTXR, Health Care | Tagged | Comments Off on Citius Announces Its Intention to Spin-Off I/ONTAK

Citius Pharma 22Q1 Update

Citius Pharmaceuticals (CXTR) is a specialty pharmaceutical company focused on the development of five potential products: (1) Mino-Lok, an antibiotic lock solution to treat and salvage infected central venous catheters (CVCs) in patients with catheter-related bloodstream infections (CRBSIs); (2) I/ONTAK, … Continue reading

Posted in CTXR, Health Care | Tagged | Comments Off on Citius Pharma 22Q1 Update

Citius Pharma Raises $71 million in Equity Unit Offering

Citius Pharmaceuticals (CXTR) is a specialty pharmaceutical company focused on the development of four potential products: (1) Mino-Lok, an antibiotic lock solution to treat and salvage infected central venous catheters (“CVCs”) in patients with catheter-related bloodstream infections (“CRBSIs”); Halo-Lido, a … Continue reading

Posted in CTXR, Health Care | Tagged , | Comments Off on Citius Pharma Raises $71 million in Equity Unit Offering